Literature DB >> 15475275

[Risks and benefits of cardiac surgery in Down's syndrome with congenital heart disease].

B Stos1, G Dembour, C Ovaert, C Barrea, A Arape, M Stijns, T Sluysmans.   

Abstract

UNLABELLED: Down's syndrome is the most frequent chromosomic anomaly. Fifty percent are associated with a congenital heart disease. Life expectancy and quality of life are increasing since 15 years with improving surgical techniques. PATIENTS AND METHODS: This study presents 73 patients with Down's syndrome who underwent a surgical repair of congenital heart disease between 1992 and 2002. Among them, 37 (50.6%) had a complete atrio-ventricular septal defect (AVSD) and 36 an other anomaly.
RESULTS: Five children died in the post operative period: all had an AVSD. Two late deaths occurred due to extra cardiac causes during the follow up. Two children who underwent a repair of AVSD had to be reoperated. The majority of the children are doing well, without any cardiac symptom. Thirty-eight percent of patients with AVSD repair have a middle mitral or tricuspid regurgitation and three had a massive mitral or tricuspid regurgitation. One child presents neurological sequelae related to surgery.
CONCLUSION: Congenital heart diseases in Down's syndrome can be repaired with a limited risk of death. Final results are good for many children with significant improvement of the quality of life and life expectancy.

Entities:  

Mesh:

Year:  2004        PMID: 15475275     DOI: 10.1016/j.arcped.2004.05.016

Source DB:  PubMed          Journal:  Arch Pediatr        ISSN: 0929-693X            Impact factor:   1.180


  2 in total

1.  Survival analysis of Down syndrome cohort in a tertiary health care center in India.

Authors:  Risha Nahar; Udhaya Kotecha; Ratna Dua Puri; Ravindra Mohan Pandey; Ishwar Chander Verma
Journal:  Indian J Pediatr       Date:  2012-07-26       Impact factor: 1.967

2.  Cardiac abnormalities of Sudanese patients with Down's syndrome and their short-term outcome.

Authors:  S K Ali
Journal:  Cardiovasc J Afr       Date:  2009 Mar-Apr       Impact factor: 1.167

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.